a public good project by the
Synthesis
Company
of California

© 2026

Muya Xiong | doi.page

0 works0 citations0 h-index

Muya Xiong

Chinese Academy of Sciences(CN)Shanghai Institute of Materia Medica(CN)University of Chinese Academy of Sciences(CN)

Publications by Year

Research Areas

Computational Drug Discovery Methods, SARS-CoV-2 and COVID-19 Research, Ubiquitin and proteasome pathways, Immune cells in cancer, interferon and immune responses

Most-Cited Works

→ What coronavirus 3C‐like protease tells us: From structure, substrate selectivity, to inhibitor design(2021)128 cited
→ Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir(2023)101 cited
→ Structural basis of ligand binding modes at the human formyl peptide receptor 2(2020)100 cited
→ In Silico Screening-Based Discovery of Novel Inhibitors of Human Cyclic GMP–AMP Synthase: A Cross-Validation Study of Molecular Docking and Experimental Testing(2020)66 cited
→ Bispecific prodrug nanoparticles circumventing multiple immune resistance mechanisms for promoting cancer immunotherapy(2021)52 cited
→ USP28 and USP25 are downregulated by Vismodegib in vitro and in colorectal cancer cell lines(2020)36 cited

→ In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease(2022)

25 cited

→ Allosteric Regulation of Hsp90α’s Activity by Small Molecules Targeting the Middle Domain of the Chaperone(2020)21 cited

→ Unraveling the catalytic mechanism of SARS-CoV-2 papain-like protease with allosteric modulation of C270 mutation using multiscale computational approaches(2023)19 cited

→ Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease(2023)18 cited